EDEM2

Across TCGA pan-cancer cohorts, EDEM2 Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated EDEM2 data layer compared with 27 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher EDEM2 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated EDEM2 expression acts as an unfavorable survival marker.

LIHC, COAD, and LUSC are the cancer types where EDEM2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	DFS	Median	All	0.094	0.555	.002	15	view →
COAD	DFS	Median	II,III,IV	0.582	0.757	.025	10	view →
LUSC	DFS	Median	III,IV	0.079	0.751	.024	9	view →
LUAD	OS	Median	III,IV	0.223	0.663	.034	9	view →
LGG	OS	Median	All	0.324	0.811	.012	6	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
SARC	DFS	Median	All	0.169	0.517	.046	3	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

EDEM2–LIHC (DFS)

Open the LIHC breakdown →